Development and Commercialization Rights Sample Clauses
The Development and Commercialization Rights clause defines which party has the authority to develop, manufacture, and market a product or technology covered by the agreement. Typically, this clause outlines the scope of rights granted, such as whether they are exclusive or non-exclusive, and may specify geographic regions, fields of use, or milestones that must be met. By clearly allocating these rights, the clause ensures that both parties understand their roles and expectations, reducing the risk of disputes and facilitating effective collaboration or commercialization efforts.
POPULAR SAMPLE Copied 4 times
Development and Commercialization Rights. Subject to any co-funding/co-promotion rights granted to Myogen pursuant to Section 3.5 hereof, NIBRI, its Affiliates and/or sublicensees, if any, shall have sole rights, even as to Myogen, in the Licensed Field to develop and manufacture on a commercial scale the Development Candidate, the related Drug Product, and the active ingredient in such Drug Product in the Territory, and to commercialize, manufacture, promote, sell, book sales, and distribute each Drug Product and/or the active ingredient in such Drug Product in each country in the Territory. (The foregoing right to manufacture is subject to any applicable United States statutory requirement that technology the development of which was funded in part by the United States government must be manufactured domestically, unless the United States government shall waive such requirement.) NIBRI and its Affiliates, in their sole discretion, shall select, file, and own all rights to any and all trademarks and trade dress relating to the Drug Product.
Development and Commercialization Rights. From and after the Amendment Date and during the Term, as between the Parties, Incyte shall, subject to Sections 3.1(a), 4.3 and 5.3 of the Original Agreement and Section 3.3 and Section 5.1 of this Amendment, have the exclusive, world-wide right and authority to Develop and Commercialize Products, Licensed Antibodies, [********] Products, and [********] Antibodies (but, for clarity, not Multispecific Antibodies, which both Parties may pursue) in the Field, and to make all decisions with respect to the same, including, subject to Section 5.1 of this Amendment, the sole right to conduct Clinical Trials, file and maintain all Regulatory Approvals, and select and monitor distributors, in each case solely in the Field.
Development and Commercialization Rights. Novartis, its Affiliates and sublicensees shall have sole and worldwide rights, even as to Infinity, to develop, commercialize, manufacture, promote, sell, and distribute each Optioned Lead Program, Optioned Lead Program Compound or Licensed Drug Product in the Field. The foregoing right to manufacture is subject to any applicable United States statutory requirement that technology, the development of which was funded in part by the United States government, must be manufactured domestically, unless the United States government shall waive such requirement. As between Novartis and Infinity, Novartis, its Affiliates and sublicensees, in their sole discretion, shall select, file, and own all rights to any and all trademarks and trade dress relating to the Drug Product which trademarks are not then trademarks of Infinity.
Development and Commercialization Rights. Except as provided in this Section 4.10 or Section 4.11.1(c), ELAN shall have the exclusive right during the Term to Develop Clinical Candidates and Commercialize Products in the Territory.
Development and Commercialization Rights. The rights granted to Novartis pursuant to Section 2.2 are exclusive to Novartis, even as to Hybridon, subject to Hybridon's right to perform its obligations under the Collaboration Agreement and subject to 35 USC Sections 200-212, 37 CFR Section 401 et seq. and related governmental implementing regulations, as applicable.
Development and Commercialization Rights. 4.1 Subject to Section 4.2, IDEC will have full scientific and management authority and control in connection with the DEVELOPMENT of COMPOUND under IDEC's IND; *_______* Indicates that material has been omitted and confidential treatment has been requested therefor. All such omitted material has been filed separately with the Secretary of Commission in the Company's Application Requesting Confidential Treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
Development and Commercialization Rights. BII hereby grants to Inspire, and Inspire hereby accepts, with effect from the Effective Date until the end of the Inspire Commercialization Period, an exclusive right and license in the Field under the BII Patents and BII Know-How (without the right to sublicense in the United States, but with the right to sublicense in Canada) to develop, use, market, distribute and sell the Product in the Inspire Territory.